InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2023-01-30 | Daniel Goldman(D-NY10) | house | Sale | $1,001 - $15,000 |
No financial data available for ESALY.
Company may not file with SEC or CIK is unresolved.
Alzheimer's Disease Drug Development: Another Lost Year
Catalyst Pharmaceuticals: Cheap For A Reason
Biogen And Eisai's Leqembi: A Dose Of Reality For Alzheimer's Disease
Senators urge swift action to expand Medicare coverage for Alzheimer’s therapies
Eisai exec expects full approval of Alzheimer's therapy Leqembi this summer - CNBC
Biogen expects new Alzheimer’s drug to weigh on 2023 outlook
Anavex hits two-month high after Q1 FY23 results
Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Call Transcript